News updates

Report on long-lasting symptoms following HPV-vaccination

The Netherlands Pharmacovigilance Centre Lareb has conducted a follow-up study concerning 231 reports of long-lasting symptoms (durat...

Survey on support needed for optimizing patient reporting

As WHO Collaborating Centre for Pharmacovigilance in Education and Patient Reporting, the Netherlands Pharmacovigilance Centre Lareb ...

Cisplatin and peripheral arterial thromboembolic events

Cisplatin (generic, Platosin®), member of the platinum-containing anti-cancer drugs, is indicated for the treatment of several types of...

Proton pump inhibitors and fundic gland polyps

The Netherlands Pharmacovigilance Centre Lareb received 8 reports of gastric polyps in association with proton pump inhibitors (PPIs). Proton pu...

Pilot to facilitate the reporting of ADRs in hospitals

ADRs in patients admitted to the hospital or in outpatients can easily report an ADR with only the patient identification number, the su...

Educational package for medical students

Lareb, in collaboration with the Dutch Society for Clinical Pharmacology and Biopharmacy (NVKF&B) and the Research and Expertise Centre in Pharmac...

Experiences with consumer reporting in Portugal

New pharmacovigilance legislation allows consumers to report adverse drug reactions (ADRs) directly to competent authorities in all European Un...

Post-Menopausal Vaginal Hemorrhage Related to the Use of a Hop-Containing Phytotherapeutic Product

Lareb recently published a case-report about two 54-year-old women who developed abdominal c...

Dabigatran (Pradaxa) and oesophageal injury

Dabigatran is an oral anticoagulant. Dabigatran is used for thrombosis and thromboprophylaxis after total hip or knee replacement, as well as the p...